Lit­tle Abi­vax sees volatile shares rock­et up on a (very ear­ly-stage) re­port of an HIV break­through

Abi­vax is wit­ness­ing the lat­est gy­ra­tion in its stock price af­ter claim­ing it’s gath­ered ev­i­dence of suc­cess in elim­i­nat­ing a sig­nif­i­cant amount of the reser­voirs of HIV that linger in pa­tients. But it’s ear­ly days yet for this drug and a com­pa­ny that has seen plen­ty of ups and downs over the last year.

The Paris-based biotech {$AB­VX.PA} says that in a small study with 30 HIV pa­tients — split 3-1 on drug and place­bo — ABX464 was com­bined with their cur­rent an­ti­retro­vi­ral reg­i­men to test its ef­fect af­ter 28 days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER